Pembrolizumab with pemetrexed and platinum-based chemotherapy for untreated non-small-cell lung cancer (CDF Review of TA557) – Final appraisal document

In DRAFT guidance, NICE recommends pembrolizumab with pemetrexed and platinum chemotherapy as an option for untreated, metastatic, non-squamous NSCLC in adults whose tumours have EGFR-positive or ALK-positive mutations, if it is stopped at 2 years (earlier if disease progresses).

Source:

National Institute for Health and Care Excellence